

IN THE CLAIMS:

Please cancel claim 7.

Please amend claim 1 as follows.

1. (twice amended) A composition capable of inducing an immune response in a mammal to cytotoxic T cell epitopes of a full length protein wherein the composition comprises a unit dose of [an] *Bacillus anthracis* anthrax protective antigen and said full length protein bound to an anthrax protective antigen binding protein, wherein the molar ratio of protective antigen to the full length protein bound to the anthrax protective antigen binding protein is greater than one, and wherein the anthrax protective antigen binding protein comprises at least about the first 250 amino acid residues of the lethal factor of *Bacillus anthracis* and less than all of the amino acid residues of the lethal factor.

REMARKS

Claims 1-6 are pending in the present application. Appendix A shows the "Version with markings to show changes made." Appendix B provides the pending claims for the Examiner's convenience.

*Objection to the specification*

Applicants have amended the specification to claim priority to the parent divisional application USSN 08/937,276.

*Rejection under 35 USC 112, first paragraph: enablement*

Claims 1-7 were rejected as allegedly lacking enablement for encompassing intact LF, which would cause cell death when administered to cells. Applicants have amended claim 1 to incorporate the elements of claim 7, which recites that the LF has at least amino acids 1-254 but less than all of the amino acids of lethal